Capital Advantage Lowers stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Capital Advantage reduced its stake in Johnson & Johnson by 0.26% during the most recent quarter end. The investment management company now holds a total of 9,556 shares of Johnson & Johnson which is valued at $1.1 Million after selling 25 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on May 23, 2016.Johnson & Johnson makes up approximately 0.38% of Capital Advantage’s portfolio.

Other Hedge Funds, Including , Vident Investment Advisory boosted its stake in JNJ in the latest quarter, The investment management firm added 42,400 additional shares and now holds a total of 64,910 shares of Johnson & Johnson which is valued at $7.3 Million. Johnson & Johnson makes up approx 0.51% of Vident Investment Advisory’s portfolio.Efg Asset Management (americas) Corp. boosted its stake in JNJ in the latest quarter, The investment management firm added 1,779 additional shares and now holds a total of 4,488 shares of Johnson & Johnson which is valued at $505,528. Johnson & Johnson makes up approx 0.26% of Efg Asset Management (americas) Corp.’s portfolio. Portland Investment Counsel added JNJ to its portfolio by purchasing 3,014 company shares during the most recent quarter which is valued at $342,270. Johnson & Johnson makes up approx 0.66% of Portland Investment Counsel’s portfolio.

Johnson & Johnson opened for trading at $113.04 and hit $113.34 on the upside on Friday, eventually ending the session at $113.06, with a gain of 0.14% or 0.16 points. The heightened volatility saw the trading volume jump to 46,47,024 shares. Company has a market cap of $310,988 M.

On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.